18 Nov

Tesaro Rises 0.8%, Trades above Its 50-Day Moving Averages

WRITTEN BY Peter Neil

Moving averages of XBI

In this article, we’ll see the different moving averages of the SPDR S&P Biotech ETF’s (XBI) holdings. As of November 17, 2015, 60% of XBI’s stocks are trading above their 20-day moving averages, 45% are trading above their 50-day moving averages, and 31% are trading above their 100-day moving averages.

Some of the stocks that are trading above their 50-day moving averages are Myriad Genetics (MYGN), Prothena (PRTA), and Seattle Genetics (SGEN) at 2.1%, -3.3%, and 3.5%, respectively.

Tesaro Rises 0.8%, Trades above Its 50-Day Moving Averages

The above graph represents the percentage of XBI’s stocks that are trading above their 20-, 50-, and 100-day moving averages. Out of 101 stocks within XBI’s portfolio, 61 are trading above their 20-day moving averages, 45 are trading above their 50-day moving averages, and 31 are trading above their 100-day moving averages.

Tesaro launches Varubi in the US, stock rose by 0.8%

Tesaro (TSRO) rose by 0.8% on November 17, 2015. The stock rose on the news of the launch of its drug Varubi in the United States.

As per its press release, TSRO announced, “VARUBI™ (rolapitant), an NK-1 receptor antagonist, is now available in the United States. The U.S. Food and Drug Administration (FDA) approved VARUBI on Sept. 1, 2015, for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.”

TSRO closed at $48.36 and was trading above its 50-day moving average but below its 100-day moving average. TSRO has a book value of $3.74. With its current price, the stock is trading at a price-to-book value (PBV) of 12.92x. TSRO has a weight of 0.9% in XBI’s portfolio.

Latest articles

Goldman Sachs (GS) settled a lawsuit that alleged it rigged bond prices. Also, Deutsche Bank agreed to pay a fine of $15 million to settle a lawsuit.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.

In the November 14 trading session, Aurora Cannabis (ACB) stock fell 12.7% from the previous session during after-hours trading.

Strategy Analytics reported that Apple could lead the 5G smartphone market in 2020, outshining Samsung—the current leader in the global 5G market.

This week has been tough for the cannabis sector. Cronos Group and Canopy Growth reported lower-than-expected earnings, and the sector ETFs dropped.

Yesterday, Argus Research upgraded Uber stock from “hold” to “buy.” Let's look at Uber and Lyft’s recent analyst rating changes.